Quick Answer
Anixa Biosciences Inc reported Operating Income of -$11.70 million for fiscal year 2025.
Anixa Biosciences Inc Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$11.70M | +15.4% |
| 2024 | -$13.83M | -25.6% |
| 2023 | -$11.01M | +20.6% |
| 2022 | -$13.88M | -5.6% |
| 2021 | -$13.14M | -31.6% |
| 2020 | -$9.98M | +16.1% |
| 2019 | -$11.89M | +16.8% |
| 2018 | -$14.29M | -135.2% |
| 2017 | -$6.08M | -34.7% |
| 2016 | -$4.51M | -377.3% |
| 2015 | -$944.8K | +81.3% |
| 2014 | -$5.04M | +36.3% |
| 2013 | -$7.92M | -91.5% |
| 2012 | -$4.13M | +17.8% |
| 2011 | -$5.03M | +4.2% |
| 2010 | -$5.25M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | -$2.72M | +19.8% | -11.5% |
| July 31, 2025 | -$2.44M | +32.2% | +18.9% |
| April 30, 2025 | -$3.00M | +13.4% | +11.3% |
| January 31, 2025 | -$3.39M | +6.2% | +5.7% |
| July 31, 2024 | -$3.59M | -26.3% | -3.6% |
| April 30, 2024 | -$3.47M | -35.4% | +3.9% |
| January 31, 2024 | -$3.61M | -41.2% | -26.9% |
| July 31, 2023 | -$2.84M | -1.7% | -11.1% |
- Anixa Biosciences Inc showed an increase of +15.4% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, Anixa Biosciences Inc’s operating income has declined by 123.0% (from -$5.25 million to -$11.70 million).
- The most recent figure is from Anixa Biosciences Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on January 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: